Healthcare facilities company Shalby announced Q2FY23 results: Total Revenues of Rs. 1,830 million, growth of 13.5% YoY (excluding vaccination and covid revenue) EBITDA of Rs. 437 million with EBITDA margins of 24% Profit After Tax was Rs. 218 million, growth of 31% YoY Basic EPS of Rs. 2.03, growth of 32% YoY Bed occupied during the quarter were 600, with occupancy rate of 16% In patients count of 12,606, growth of 19% YoY Total Surgery count of 6.806, growth of 10% YoY Result PDF
Healthcare Facilities firm Shalby Announced Q1FY23 Result : Shalby Hospital Business Registered Quarterly Revenues of Rs. 1,810 million up by 19%, and EBITDA of Rs. 428 million up by 32% with margins of 24%, primarily driven by increase in InPatients count by 15% and Total Surgery count up by 30% quarter on quarter basis. Total Revenues of Rs. 1,810 million, growth of 19% QoQ EBITDA of Rs. 426 million with EBITDA margins of 24% Profit After Tax was Rs. 214 million, growth of 36% QoQ Basic EPS of Rs. 1.99, growth of 37% QoQ Bed occupied during the quarter were 557, with occupancy rate of 45% In patients count of 11,044, growth of 15% QoQ Total Surgery count of 7,211, growth of 30% QoQ Mr. Shanay Shah, President said: “I am happy to report that Shalby has registered ever highest Revenue in the first quarter of FY23 with high double growth of elective surgeries. During the quarter, a total of 7,211 elective surgeries were performed, grew by 30% QoQ as compared to 5,558 in Q4 FY22. We saw a jump of 15% for In-patients counts in Q1 FY23. Occupied beds increased to 557 up by 12% in Q1 FY23 as compared to 499 in Q4 FY22. ARPOB an ALOS were recorded at Rs.35,304 and 4.08 respectively in Q1 FY23 vis-à-vis Rs 33,707 and 4.12 in the previous quarter. Our core specialty such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 84% to the revenues respectively in Q1 FY23. International revenue recorded at Rs 24 million, grew by in 47% QoQ with majority of the patients are flying from Kenya, Tanzania, Uganda, Sudan, UAE, Nepal and Bangladesh in Q1 FY23. Home care business has shown a good pick up with revenue of Rs. 21.5 million, grew by 13% QoQ with patient served count of 5,868 in Q1 FY23. The Shalby Academy vertical also showed great acceptance with 578 students enrolled for various healthcare programs during Q1 FY23. Our Realized Return on Capital Employed from hospital business has increased to 17% in Q1 FY23 from 12% in Q4 FY22. We have closed the quarter with a net cash balance of Rs. 439 million at group level and are well positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient satisfaction. We are proud to make a positive difference in people lives. Result PDF
Healthcare Facilities firm Shalby declares Q4FY22 result: Hospital Performance Highlights: FY2022 vs FY2021 Total Revenues of Rs. 6,598 million, growth of 54% YoY Operating EBITDA of Rs. 1,426 million with EBITDA margins of 22% Profit After Tax was Rs. 698 million, growth of 63% YoY Realized Return on Capital Employed improved to 14%, compared to 8% in FY21 Bed occupied during the quarter were 563, with occupancy rate of 46% In patients count of 40,603, growth of 41% YoY Total Surgery count of 20,240, growth of 70% YoY Hospital Performance Highlights: Q4 FY2022 vs Q4 FY2021 Total Revenues of Rs. 1,523 million, growth of 6% YoY Operating EBITDA of Rs. 323 million with EBITDA margins of 21% Profit After Tax was Rs. 157 million, growth of 42% YoY Bed occupied during the quarter were 499, with occupancy rate of 42% In patients count of 9,629, growth of 11% YoY Total Surgery count of 5,558, growth of 1.6% YoY Mr. Shanay Shah, President said: “Shalby delivered a strong performance during the year and I am pleased that Shalby as a hospital group was able to support the Covid-19 patients especially during the second wave of Covid-19 which impacted the lives of many. In the second half of the year, we saw a strong recovery of elective surgeries which continues to drive our core specialty revenues. During the year, a total of 20,240 elective surgeries were performed, an increase of 70% on YoY basis. We saw a strong jump of 41% for in-patient count and travel of international patients has also resumed. Occupied beds increased to 563 up by 31% in FY22 from 428 occupied beds in FY21. ARPOB and ALOS were recorded at Rs. 33,707 and 4.55 days in FY22 vis-a-vis Rs. 27,400 and 5.42 days in FY21. Our core specialty such as Arthroplasty, Critical care & General Medicine, Oncology, Cardiac Science, Orthopaedic, Neurology and Nephrology contributed 29%, 22%, 9%, 8%, 8%, 5% and 3% to the revenues respectively. Continued generation of strong cash flow from hospital operation of Rs. 1,238 million helped to strengthen our balance sheet further. Our Realized Return on Capital Employed has increased from 8% in FY21 to 14% in FY22. We have closed the year with a net cash balance of Rs. 475 million at group level and are well positioned to fund our strategic growth plans. Shalby has evolved and become a true multi-specialty hospital group which is backed by clinical excellence and patient delight. Shalby Jaipur created history with 200 Joint Replacement surgeries in a month by a single Orthopedic surgeon. We at Shalby units, have successfully completed total 28 Kidney and Liver transplants in FY22. We continue to focus improving internal systems and processes. We have also successfully implemented SAP in February 2022 and this strategic implementation aims to strengthen our financial & operational processes by improvising database management, administration, security, real-time access and advance analytics to support the business decisions.” Result PDF